

Post Available for the Medicines for Women's Health Expert Advisory Group

Advert

The Interim Devices Working Group (IDWG) is looking to appoint lay member to the In Vitro Diagnostics Expert Advisory Group (IVD EAG).

The IVD EAG is a subgroup of the IDWG that provides independent expert advice to the Medicines and Healthcare products Regulatory Agency (MHRA) on the development, implementation, and evaluation of IVD devices. The group's objective is to ensure that IVD regulations, guidance and regulatory practices support innovation, maintain high standards of safety and efficacy, and align with international and domestic leading practices.

IVD EAG is formed of experts in the field of in vitro diagnostics, including scientists, engineers, clinicians, pathologists, and diagnostics regulatory specialists. Representatives from relevant government departments and agencies, e.g. NICE, Devolved Administrations, NIHR, UK HSA, etc. Non-industry stakeholders, including representatives from academia and learned organisations such as the Royal Colleges and Biomedical faculties and patient or patient group representatives to ensure patient perspectives are considered.

The IVD EAG provides advice and recommendations to IDWG and MHRA on:

- The development and implementation of IVDs, including policies, regulations, and guidance.
- The research, development, and evaluation of certain IVDs, including their clinical evidence and performance.
- · Applications for exceptional use authorisation of IVDs.
- · Applications for Coronavirus test device approvals.
- The stakeholders, including professional organisations and patient groups, to gather diverse perspectives and insights.
- Emerging trends and advancements in IVD technologies to ensure the regulatory frameworks remain current with technological advancements.
- Matters arising from scientific, clinical, or regulatory evidence uncertainty and where leading practice guidance may be required.

IVD EAG also input into MHRA statements, advice, and recommendations.

IVD EAG lay members are not employed by MHRA. IVD EAG lay members are independent from MHRA and provide their time on a voluntary basis.

The closing date for applications is 6 February 2026.

Role and responsibilities of the Lay Members of the IDWG's In Vitro Diagnostics Expert Advisory Group

As a lay member you will:

- Take full account of the evidence in making decisions and consider the analysis and interpretation of the evidence prepared by MHRA.
- Consider equality, diversity and inclusion in all of the EAG discussions.
- Have a flexible attitude, ability and enthusiasm to work as a team member
- Assessing benefit and risk in relation to evidence presented in order to contribute expertise to generate effective actions to mitigate risk
- Read papers in advance of meetings
- Occasionally comment on documents in between meetings by email
- Keep the work of the EAG confidential Declare conflicts of interest and adhere to the Code of Practice (<u>link</u>)

Essential Criteria

The Lay Member must be able to demonstrate the qualities, skills and experience to meet all the essential criteria for appointment.

- Current or previous experience of committee membership(s);
- Be able to assimilate and interpret complex scientific information and formulate evidencebased comments /advice at short notice;
- Be able and prepared to contribute actively to the work of the EAG by providing a nonspecialist contribution to discussions about patient diagnostics and public perspectives;
- Be a skilled communicator:
- Be willing to develop a working knowledge and understanding of UK MDR and EU IVDR regulatory framework and procedures;
- Maintain strict confidentiality with respect to the work of the EAG;
- Be willing to declare conflicts of interest and comply with the Code of Practice;
- Be committed to the values of selflessness, integrity, objectivity, accountability, professionalism, impartiality and consistency.

The main role of the lay member is to ensure that the perspective of patients, carers and the general public are represented and considered in all aspects of the committee's work. Our lay members come from a variety of different backgrounds and generally will not be an expert in a field of relevance to the EAG in which they are a member.

Lay members are individuals who sit on our advisory committees to provide a non-specialist contribution to discussions. The phrase 'lay member' refers to a member of one of our advisory committees or groups who has personal experience of living with a condition and its current therapeutic environment. The phrase could also refer to someone from a community affected by the advice provided by the advisory committee or group.

Lay members fulfil an important committee role by contributing a patient perspective to the work of the advisory committee or group, or by representing the broader community potentially affected by their advice. Lay members have full rights to participate in the discussion, therefore must comply with the Code of Practice.

People with healthcare professional qualifications or professional experience of working in an area relevant to the work of the advisory committee or group, are not eligible to apply for a lay member role.

Remuneration

You may claim travel and subsistence expenses, which are properly and necessarily incurred
in carrying out your role and responsibilities as Member of the IVD EAG, in line with travel and
subsistence policy and rates for the MHRA. A copy of the policy and rates is available from
the MHRA.

Time Commitment

• 4 meetings per year, held virtually/in person.

Tenure of office

3 years

How to Apply

If you are interested in joining the **IVD EAG**, please email your application form, completed declaration of interests form and monitoring form to <u>CSTrecruitment@mhra.gov.uk</u>, quoting the position and reference **IVDEAG25-3a** in the subject field. Please ensure that you provide evidence to support how you meet all of the essential criteria.

If you require an alternative format, please call the Appointments Team on 020 3080 6060 quoting the reference **IVDEAG25-3a**.

The closing date for applications is 6 February 2026. The MHRA value and promote diversity and encourage applications from all sections of the community.

